Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?

被引：4
|
作者：
Doki, Y [1 ]
Monden, M [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Suita, Osaka 5650871, Japan
来源：
JOURNAL OF GASTROENTEROLOGY | 2004年 / 39卷 / 12期
关键词：
D O I：
10.1007/s00535-004-1508-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1228 / 1229
页数：2
相关论文
共 50 条
  • [31] Pathological predictors of the response to platinum-based chemotherapy in pancreatobiliary neuroendocrine carcinoma
    Furukawa, Takaaki
    Ozaka, Masato
    Takamatsu, Manabu
    Okamoto, Takeshi
    Ishitsuka, Takahiro
    Yamada, Manabu
    Nakagawa, Hiroki
    Mie, Takafumi
    Takeda, Tsuyoshi
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Sasaki, Takashi
    Sasahira, Naoki
    ANNALS OF ONCOLOGY, 2023, 34 : S1438 - S1438
  • [32] The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma
    Zanotti, KM
    Belinson, JL
    Kennedy, AW
    Webster, KD
    Markman, M
    GYNECOLOGIC ONCOLOGY, 1999, 74 (02) : 272 - 277
  • [33] Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy
    Kim, Ji-Won
    Lee, Jeong-Ok
    Han, Sae-Won
    Oh, Do-Youn
    Im, Seock-Ah
    Kim, Tae-You
    Bang, Yung-Jue
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 125 - 129
  • [34] Selecting the best candidates for platinum-based adjuvant chemotherapy after radical cystectomy in pN plus bladder cancer patients
    Afferi, L.
    Lonati, C.
    Montorsi, F.
    Briganti, A.
    Mari, A.
    Schulz, G. B.
    Black, P.
    Di Trapani, E.
    Karnes, R. J.
    Mir, M. C.
    Rink, M.
    Zamboni, S.
    Antonelli, A.
    Tafuri, A.
    Krajewski, W.
    Xylinas, E.
    Soria, F.
    Teoh, J. Y.
    Mattei, A.
    Albisinni, S.
    Roghmann, F.
    Alvarez-Maestro, M.
    Shariat, S. F.
    Moschini, M.
    EUROPEAN UROLOGY, 2021, 79 : S1115 - S1116
  • [35] EFFICACY AND SAFETY OF FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH POST-OPERATIVE RECURRENCE AFTER PLATINUM-BASED ADJUVANT CHEMOTHERAPY
    Muraki, K.
    Imai, H.
    Shukuya, T.
    Ohhashi, R.
    Koyama, R.
    Mori, T.
    Murakami, H.
    Takahashi, T.
    Yamamoto, N.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 148 - 148
  • [36] Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation study
    Zhulikov, Y. A.
    Kovalenko, E. I.
    Artamonova, E.
    Evdokimova, E. V.
    Bohian, V.
    Gabrava, M.
    Kolobanova, E.
    Yugay, V. V.
    Stilidi, I. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S537 - S537
  • [37] Prognostic Significance of Hemoglobin Levels in Patients with Primary Epithelial Ovarian Carcinoma Undergoing Platinum-based Chemotherapy
    Pongsanon, Khemmawan
    Benjapibal, Mongkol
    Ruengkhachorn, Irene
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (01) : 131 - 136
  • [38] PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma
    Matsubara, Hiroaki
    Fukuda, Takeshi
    Awazu, Yuichiro
    Nanno, Shigenori
    Shimomura, Masahiro
    Inoue, Yuta
    Yamauchi, Makoto
    Yasui, Tomoyo
    Sumi, Toshiyuki
    ONCOLOGY LETTERS, 2021, 21 (02)
  • [39] Concurrent cetuximab versus platinum-based chemotherapy with radiotherapy for patients with squamous cell carcinoma of the head and neck
    Caudell, J. J.
    Sawrie, S. M.
    Spencer, S. A.
    Carroll, W. R.
    Peters, G. E.
    Nabell, L. M.
    Meredith, R. F.
    Bonner, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S451 - S451
  • [40] Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study
    Abdel-Malek, Raafat
    Shohdy, Kyrillus S.
    Abbas, Noha
    Ismail, Mohamed
    Hamada, Emad
    Abdel-Kader, Yasser
    CURRENT DRUG SAFETY, 2019, 14 (01) : 31 - 36
12345